🇺🇸 FDA
Pipeline program

AZD5492

TITANium

Phase 1 small_molecule active

Quick answer

AZD5492 for B-Cell Malignancies is a Phase 1 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).

Program details

Company
AstraZeneca AB
Indication
B-Cell Malignancies
Phase
Phase 1
Modality
small_molecule
Status
active

Clinical trials